ArticleThe Annals of thoracic surgery2019
Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.
Article in The Annals of thoracic surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 49 citations in OpenAlex.
- Dynamic Changes of ctDNA-Based MRD and Genomic Mutations Predict Prognosis in ESCC Treated With Definitive Radiotherapy.Cancer science · 2026Article
- Role of liquid biopsy in the multimodal assessment and treatment of esophageal cancer: a surgical perspective.Updates in surgery · 2026Article
- Translational feasibility of a plasmonic microarray-based liquid biopsy for KRAS codon mutation detection across tissue, plasma, and urine in early colorectal cancer.NPJ precision oncology · 2026Article
- Value of circulating free DNA methylation in the diagnosis of esophageal cancer: A systematic review and meta-analysis.Oncology letters · 2025Article
- Gene-specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study.Clinical and translational medicine · 2025Article
- Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN).ESMO open · 2025Article
- Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.Frontiers in oncology · 2025Review
- Preoperative inflammatory burden index for prognostication in esophageal squamous cell carcinoma undergoing radical resection.Scientific reports · 2024Article
- Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.JCO precision oncology · 2024Article
- The Correlation between Plasma Circulating Tumor DNA and Radiographic Tumor Burden.The Journal of molecular diagnostics : JMD · 2024Review
- Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab.Nature communications · 2024Article
- Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.British journal of cancer · 2024Review
- Circulating cell-free DNA-based methylation pattern in plasma for early diagnosis of esophagus cancer.PeerJ · 2024Review
- Liquid Biopsies: Emerging role and clinical applications in solid tumours.Translational oncology · 2023Article
- Combining Solid and Liquid Biopsy for Therapy Monitoring in Esophageal Cancer.International journal of molecular sciences · 2023Article
- Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2023Article
- Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers.International journal of molecular sciences · 2023Review
- Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.Frontiers in immunology · 2023Article
- Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.The Journal of pathology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundRecent literature has demonstrated the potential of "liquid biopsy" and detection of circulating tumor (ct)DNA as a cancer biomarker. However, to date there is a lack of data specific to esophageal adenocarcinoma (EAC). This study was conducted to determine how detection and quantification of ctDNA changes with disease burden in patients with EAC and evaluate its potential as a biomarker in this population.
methodsBlood samples were obtained from patients with stage I to IV EAC. Longitudinal blood samples were collected from a subset of patients. Imaging studies and pathology reports were reviewed to determine disease course. Tumor samples were sequenced to identify mutations. Mutations in plasma DNA were detected using custom, barcoded, patient-specific sequencing libraries. Mutations in plasma were quantified, and associations with disease stage and response to therapy were explored.
resultsPlasma samples from a final cohort of 38 patients were evaluated. Baseline plasma samples were ctDNA positive for 18 patients (47%) overall, with tumor allele frequencies ranging from 0.05% to 5.30%. Detection frequency of ctDNA and quantity of ctDNA increased with stage. Data from longitudinal samples indicate that ctDNA levels correlate with and precede evidence of response to therapy or recurrence.
conclusionsctDNA can be detected in plasma of EAC patients and correlates with disease burden. Detection of ctDNA in early-stage EAC is challenging and may limit diagnostic applications. However, our data demonstrate the potential of ctDNA as a dynamic biomarker to monitor treatment response and disease recurrence in patients with EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.